In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Fact checked by Nick Blackmer GLP-1 medications like Ozempic and Wegovy have become popular for helping people lose weight or ...

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

Ozempic maker Novo Nordisk says it has developed a compound that’s shown to be a one-two punch for appetite suppression and ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A total of 63 oral GLP-1 receptor drugs are in development, with four phase 3 products competing for the first approval of an oral version of the drug. Novo Nordisk's Rybelsus, which is FDA approved ...

GLP-1s have been heralded for their ability to suppress appetite but did you know that GLP-1 is a natural hormone you can stimulate without injections.